DESCOVY® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.
Limitation of Use: DESCOVY FOR PrEP® is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.
Initiating DESCOVY FOR PrEP®1
Implementation fits within the paradigm of preventive health in primary care
Here's a brief overview of what you need to do prior to initiating DESCOVY FOR PrEP. Select each section to learn more about screening and monitoring patients:
- DESCOVY FOR PrEP must be prescribed only to patients confirmed to be HIV negative
- Do not initiate DESCOVY for HIV-1 PrEP if signs or symptoms of acute HIV-1 infection are present unless negative HIV status is confirmed
- If screening or symptoms consistent with acute HIV-1 infection indicate an individual may have become HIV positive while taking DESCOVY FOR PrEP, convert the HIV-1 PrEP regimen to an HIV treatment regimen until HIV-negative status is confirmed
- Test and monitor for chronic HBV and, if negative, consider vaccination
- Individuals should strictly adhere to the recommended DESCOVY FOR PrEP dosing schedule
- The effectiveness of DESCOVY FOR PrEP in reducing the risk of acquiring HIV-1 is strongly correlated with adherence
- Some individuals, such as adolescents, may benefit from more frequent visits and counseling
- DESCOVY FOR PrEP is not recommended in individuals with CrCl <30 mL/min
- In all patients, assess serum creatinine, estimated CrCl, urine glucose, and urine protein on a clinically appropriate schedule
- In patients with chronic kidney disease, assess serum phosphorus
- DESCOVY FOR PrEP must be prescribed only to patients confirmed to be HIV negative
- Do not initiate DESCOVY for HIV-1 PrEP if signs or symptoms of acute HIV-1 infection are present unless negative HIV status is confirmed
- If screening or symptoms consistent with acute HIV-1 infection indicate an individual may have become HIV positive while taking DESCOVY FOR PrEP, convert the HIV-1 PrEP regimen to an HIV treatment regimen until HIV-negative status is confirmed
- Test and monitor for chronic HBV and, if negative, consider vaccination
- Individuals should strictly adhere to the recommended DESCOVY FOR PrEP dosing schedule
- The effectiveness of DESCOVY FOR PrEP in reducing the risk of acquiring HIV-1 is strongly correlated with adherence
- Some individuals, such as adolescents, may benefit from more frequent visits and counseling
- DESCOVY FOR PrEP is not recommended in individuals with CrCl <30 mL/min
- In all patients, assess serum creatinine, estimated CrCl, urine glucose, and urine protein on a clinically appropriate schedule
- In patients with chronic kidney disease, assess serum phosphorus
Prescribe DESCOVY FOR PrEP to appropriate patients at risk for HIV. Use DESCOVY for HIV-1 PrEP to reduce the risk of HIV as part of a comprehensive prevention strategy to reduce the risk of sexually transmitted infections (STIs).
DESCOVY® Co-pay SupportHBV=hepatitis B virus.